mainecare s new medication assisted treatment mat methadone maintenance therapy mmt policy n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy PowerPoint Presentation
Download Presentation
MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy

Loading in 2 Seconds...

play fullscreen
1 / 14

MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy - PowerPoint PPT Presentation


  • 76 Views
  • Uploaded on

MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy. Kevin S. Flanigan, MD Medical Director Office of MaineCare Services. Agenda. Time Topic and Presenter 5:30- 5:40 Introduction Stefanie Nadeau, Director of MaineCare Services, DHHS

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy' - lara-love


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
mainecare s new medication assisted treatment mat methadone maintenance therapy mmt policy

MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy

Kevin S. Flanigan, MD

Medical Director

Office of MaineCare Services

agenda
Agenda

Time Topic and Presenter

5:30- 5:40 Introduction Stefanie Nadeau, Director of MaineCare Services, DHHS

5:40- 5:50 Medication Assisted Treatment Resources,

Tracy Weymouth, State Opioid Treatment

Authority, Office Substance Abuse and Mental

Health Services

5:50- 6:30 Suboxone Redesign Planning and Partnership,

Kevin Flanigan MD, Medical Director, MaineCare

Services, DHHS

6:30- 6:45 Prior Authorization (PA) Process, Kevin Flanigan

MD, Medical Director, MaineCare Services, DHHS

6:45- 7:00 Questions and Answers

medication assisted treatment resources
Medication Assisted Treatment Resources
  • Responsible Opioid Prescribing: A Clinician’s Guide by Scott M. Fishman MD
  • Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction TIP 40
  • Medication-Assisted Treatment For Opioid Addiction in Opioid Treatment Programs TIP 43
  • Buprenorphine: A Guide for Nurses TAP 30
  • Clinical Drug Testing in Primary Care TAP 32
  • Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals – New England ATTC Addiction Technology Transfer Center Network www.attcnetwork.org
  • Ohio – Low Dose protocol for the Use of Buprenorphine and Suboxone
  • Vermont – Vermont Buprenorphine Practice Guidelines
suboxone demand
Suboxone Demand
  • One of the fastest growing pharmaceutical expenses in MaineCare’s pharmacy budget
  • We anticipate an increased need among MaineCare patients as with restrictions to opioid coverage and new pain management policy implementation in January 2013 there may be more members seeking addiction treatment.
suboxone changes
Suboxone Changes
  • New legislation passed in Spring 2012
    • Creates a lifetime limit of 24 months of Suboxone treatment, effective January 1, 2013
    • Retroactive application of lifetime limit
    • Prior Authorization for Suboxone treatment when found “medically necessary”
partnership
Partnership
  • MaineCare leadership requests both clinical input for recommendations and stakeholder advisement
  • Stakeholder partnership with MaineCare is key
    • Medical provider participation
    • Administrators
    • Advocate participation(patient & provider)
    • Patient participation
planning phase
Planning Phase

Starting in the summer of 2012, all partners came together to discuss the following:

  • The new law
  • Patient management and care
  • Goals of a new MaineCare policy
  • Prior Authorization (PA) process
  • Risks, benefits & options
objectives of thoughtful planning
Objectives of Thoughtful Planning
  • Stakeholder partnership
  • Clear goals for Suboxone changes
  • Evidenced-based recommendations
  • Consensus-based recommendations
successes realized from summer 2012 suboxone workgroup
Successes Realized from Summer 2012 Suboxone Workgroup
  • A collaborative effort to plan for patient management and care
  • Revised PA process
  • A new foundation for a working relationship between MaineCare, providers & patients!
new suboxone policy
New Suboxone Policy
  • New MaineCare Suboxone policy that is:
    • Created as a result of clinically appropriate recommendations
    • Sensitive to the needs of MaineCare patients
    • Supportive of evidence- based practices
    • Reflective of the Department’s budget limitations
prior authorization pa redesign
Prior Authorization (PA) Redesign
  • Prior Authorization (PA) allowed if “medically necessary”
    • What does that mean?
    • How do I get Prior Authorization?
  • Draft Suboxone Continuation PA Form
  • Draft Suboxone Restart PA Form
preamble from suboxone workgroup
Preamble from Suboxone Workgroup
  • Preamble drafted from Suboxone workgroup
  • Fundamentals of Suboxone/buprenorphine treatment
slide14

Thank you for attending today’s meeting.

If you have additional questions or comments, please email:

Kevin Flanigan MD, MaineCare Medical Director at: Kevin.Flanigan@maine.gov

All meeting materials will be posted at: